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Abstract 
Background & Objectives: Postnatal depression correlates with postpartum weight 
retention, and dysregulated cortisol metabolism is evident in depressed individuals. Cortisol 
metabolism, BMI and metabolic phenotype are robustly associated but the role of cortisol 
metabolism in postnatal mental health and weight loss has never been examined. 
Design: A longitudinal observation. 
Patients: 49 healthy women with uncomplicated pregnancy. 
Measurements: BMI and urinary steroid metabolites at 1 week and 1, 3, 6 and 12 months 
postpartum. Validated urinary steroid metabolite ratios were measured to determine the 
activities of 11β-hydroxysteroid dehydrogenases (11β-HSD) that interconvert inactive 
cortisone and active cortisol and the 5α-reductases that clear cortisol to its inactive 
metabolites. Postnatal depression symptoms were measured at 1, 6 and 12 months. 
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Results: Low 5α-reductase activity was associated with greater weight loss across the first 
year, independent of demographics, breastfeeding and depression. Postpartum BMI change 
was unrelated to postnatal depression at any time. Symptoms of postnatal depression were 
related to higher cortisol metabolite production at 12 months, independent of demographics 
and breastfeeding.  
Conclusions: Greatest weight loss in the postpartum year was associated with lower 
conversion of cortisone to cortisol and lower conversion of cortisol to its metabolites, 
supporting previous work that demonstrates the facilitative role of lower 5α-reductase and 
11β-HSD-1 in weight loss. Greater depression symptoms were associated with higher cortisol 
metabolite production rates. Whilst weight and mental health are both associated with 
dysregulation of the HPA axis, there may be different pathways towards depressed and obese 
phenotypes in healthy postpartum samples. 
 
Background 
Maternal postpartum weight trajectories are important factors in immediate and long-term 
maternal physical and mental health. Two thirds of women retain weight after pregnancy1. 
The risk of depression and anxiety is significantly higher in women who retain two or more 
BMI units at 6 months postpartum2. Women who gain excess weight during pregnancy are 
2.15 times as likely to be overweight and 4.49 times as likely to be obese two decades later3. 
Unsuccessful postpartum weight loss is a risk factor for long-term obesity1,4 and postnatal 
adiposity tends to have centralised distribution thus increasing risk of disease5. There is 
considerable variability of postpartum weight change (e.g. mean (±SD) of +1.1kg (±7.6kg) at 
14 months postpartum6) with lower weight retention predicted by married status, lower 
gestational weight gain and longer breastfeeding6. Maternal depressed mood has also been 
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associated with poorer postpartum weight loss trajectories2 and obesity is a risk factor for 
postnatal depression7.  
 
Dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis is common in obesity and 
mental health disorders, indicating a possible mechanistic link8. Women with higher prenatal 
depression scores have been shown to have higher salivary cortisol9 and maternal distress in 
pregnancy is related to plasma cortisol levels10 . However, some studies show weak 
associations11-12. This may be because relationships between pregnancy distress and 
circulating cortisol may not necessarily be linear or may vary with gestation12. For example, 
in one study of severely obese pregnant women, both very high and very low maternally 
reported anxiety was related to low serum cortisol levels13. Furthermore, higher serum 
cortisol levels in late pregnancy predicts greater postpartum weight retention in severely 
obese women13. However, serum cortisol level does not mediate between mental health and 
postpartum weight retention13. In obese individuals, circulatory cortisol concentrations are 
often normal or low14 due to enhanced excretion accompanied by increased metabolic 
clearance15. Therefore, investigation of the role of cortisol metabolism, rather than level, in 
postnatal mental health and weight loss/retention is warranted.  
 
Little is known about the metabolic underpinnings of postpartum weight change or 
postpartum mental health. Steroid hormone metabolism has been linked to insulin resistance, 
obesity and the metabolic syndrome16. Longitudinal changes in glucocorticoid metabolism 
are associated with the development of adverse metabolic phenotypes, with higher total 
glucocorticoid production linked to increased BMI and abnormal glucose tolerance17. 
Examination of the activity of the enzymes 11ß-hydroxysteroid dehydrogenase type 1 (11ß-
HSD-1, which converts inactive cortisone to cortisol), 11ß-hydroxysteroid dehydrogenase 
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type 2 (11ß-HSD-2, which converts cortisol to inactive cortisone) and 5α-reductase (which 
converts cortisol to its tetrahydrometabolites) has established their role in the development 
and maintenance of metabolic disease17. 11ß-HSD-1 is highly expressed in adipose tissue 
from obese individuals and inhibition of 11ß-HSD-1 results in weight loss and improvements 
in glycaemic control18-21. 11ß-HSD-2 is expressed in the kidney and has a role in controlling 
blood pressure via its blocking of cortisol’s activation of the mineralocorticoid receptor. 
There is a positive relationship between 5α-reductase and markers of insulin resistance22.  
 
In addition to its role in metabolic disease, cortisol metabolism is implicated in a number of 
mental health problems, particularly depression, anxiety and psychosis23-25. 5α-reductase 
inhibitors have been associated with symptoms of depression26 and depressed patients show 
lower 5α-reductase and 11ß-HSD-2 activity suggesting less clearance of cortisol24. 
Pharmacological treatment of depression for 4 weeks results in increases in 5α-reductase 
activity to levels comparable to a non-depressed control group24.  
 
Previously, we have described postpartum corticosteroid metabolism in this cohort of 
women27. 11β-HSD-1 and 11β-HSD-2 activity did not show significant changes with time. 
5α-reductase activity was low in the immediate post-partum period, increased over the initial 
3 months and then gradually stabilised, returning to levels comparable to a comparison 
female cohort who had not recently been pregnant.  However, there has been no longitudinal 
assessment of the relationship between weight change and steroid metabolism postpartum. 
Neither has the role of steroid metabolism in maternal postnatal depression been previously 
examined. Therefore, this exploratory study aimed to describe the maternal postpartum 
weight change trajectory and associated pattern of glucocorticoid metabolism in a sample of 
UK women across the first postnatal year; examine the concurrent relationships between 
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maternal glucocorticoid metabolism and maternal symptoms of postnatal depression; and 
examine the relationships between weight change and maternal glucocorticoid metabolism in 
the postpartum year independent of confounds of breastfeeding, demographics and maternal 
depression. We hypothesised that greater weight loss would be associated with lower 11β-
HSD-1 and 5α-reductase activity, increased 11β-HSD-2 activity and with a reduced total F 
metabolite production rate. We hypothesised that higher depression scores would be 
associated with greater weight retention as well as lower 5α-reductase and 11β-HSD-2 
activity. We also predicted that higher 11β-HSD-1 activity and total F metabolite production 
rate would be related to poorer mental health.      
 
Method 
Materials and Methods 
The protocol received ethical approval from Birmingham East, North and Solihull Research 
Ethics Committee, UK (ref. 10/H1206/67). All procedures contributing to this work comply 
with the ethical standards of the relevant national and institutional committees on human 
experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Birmingham 
Women’s NHS Foundation Trust granted research and development approval (ref. 
10/BWH/NO95). Women without complications during pregnancy/labour on low risk 
maternity units in Birmingham, UK were approached after labour and gave fully informed 
written consent. Mothers were visited at 1-week, 1-month, 3-, 6- and 12-months post-partum 
to collect urine samples and were weighed wearing light indoor clothing without shoes at 1-
week, 1-, 6- and 12-months. Maternal height was measured at 1-week postpartum using a 
stadiometer. Maternal weight and height were converted into BMI (kg/m2). 
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During the 1-week home visit, mothers reported their pre-pregnancy weight, pregnancy 
medical history and provided demographic information. At each time point, mothers gave a 
single urine sample and reported whether they were still breastfeeding. Mothers completed 
the Edinburgh Postnatal Depression Scale28 (EPDS), a widely used and well-validated 
screening tool for postnatal depression, at 1, 6, and 12 months postpartum. Higher scores 
indicate greater symptoms and scores of 13 or above indicate that participants are probably 
suffering from clinical depression.  
 
Urinary steroid metabolite analysis  
Spot urine samples were analysed; absolute corticosteroid concentrations were corrected per 
g of urinary creatinine to assess absolute production rates. Previous work has demonstrated 
that spot urine samples yield measures of corticosteroid activity that are very highly 
correlated with measures from 24 hour samples (r=.959) and thus spot urine samples 
accurately reflect daily corticosteroid activity29. Gas chromatography / mass spectroscopy 
(GC/MS) was used to analyse urinary corticosteroid metabolites as described elsewhere16,30. 
Solid-phase extraction was used to extract free and conjugated steroids. Steroids were 
enzymatically released from conjugation and then re-extracted. Methyloxime-
trimethylsilyethers (MO-TMS) were formed by adding internal standard (stigmasterol) prior 
to derivitization. The final derivative was dissolved in cyclohexane and transferred to a 
GC/MS autosampler vial. An Agilent 5973 instrument in selected-ion-monitoring (SIM) 
mode was used to run the samples.  
The sum of total cortisol metabolites (THF (tetrahydrocortisol), THE (tetrahydrocortisone), 
5α-THF, α-cortolone, cortisone (E), cortisol (F), β-cortolone, β-cortol, α-cortol) was used to 
measure cortisol secretion rate (total F metabolites). Here, the term total F metabolites means 
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the total of measured metabolites, not the complete excretion of all metabolites. The ratio of 
tetrahydro-metabolites of cortisol (THF + 5αTHF) to those of cortisone (THE) was used to 
measure 11β-HSD-1 activity. The ratio of urinary cortisol (F) to cortisone (E) accurately 
reflects renal 11β-HSD-2 activity (with higher F/E ratios indicating decreased 11β-HSD-2 
activity). The activity of 5α-reductase was inferred from measuring the ratio of 5αTHF/THF. 
 
Participants 
59 mothers (mean age 29±5years, mean BMI @ 1 week postpartum 26.9±3.9kg/m2) of 36 
male and 23 female infants, who had spontaneous normal vaginal deliveries without 
complications, provided informed written consent to participate and gave a series of spot 
urine samples in the postpartum year. None had any significant past medical history or were 
taking any regular medication. Mothers with gestational diabetes, preeclampsia or pregnancy 
induced hypertension were excluded. Infants born prior to 36-weeks gestation or who were 
small for gestational age were not eligible for participation. Two mothers were pregnant at 
the 12-month visit, so their data were removed from all analyses. Urine samples and 
sufficient data for calculation of BMI change was available for 49 of the women who gave 
consent to take part in the study.  
 
Statistical approach 
Statistical analysis was undertaken using IBM SPSS v22. Repeated Measures ANOVAs were 
used to examine changes across time in BMI, postnatal depression and cortisol metabolism. 
Observed power was reported. Posthoc pairwise comparisons identified the source of 
significant effects. Maternal BMI change scores (ΔBMI) at each stage were calculated. 
Positive ΔBMI implies reductions in BMI. For parsimony, total postpartum ΔBMI score was 
calculated from 1 week to 12-months postpartum and used in all analyses of relationships 
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between weight change and cortisol metabolism. Pearson’s correlation coefficients between 
demographics, breastfeeding duration, symptoms of depression and maternal steroid 
metabolism determined the necessity to control for these covariates in subsequent analyses. 
Post hoc power estimates were calculated. Bonferroni corrections were not applied given 
their unnecessarily stringent effects because we did not want to increase the risk of type II 
error in this relatively small sample, given the exploratory nature of the work. Postnatal 
depression symptoms at 1, 6 and 12 months and overall ΔBMI across the postnatal year were 
then correlated with glucocorticoid metabolism at each data collection point, using one-tailed 
partial correlation analyses controlling for maternal age, education, income, smoking, alcohol 
consumption and total breastfeeding duration. Additionally, analysis of ΔBMI glucocorticoid 
metabolism relationships were adjusted for depression. 
 
Results 
Table 1 illustrates the descriptive and demographic information of participants providing 
weight and urine measures at each time point. 
 
Table 1 about here 
The sample were affluent, well educated, relatively healthy weight, predominantly White 
British, with high initial breastfeeding rates and low levels of pregnancy smoking. 
 
BMI change across the postpartum year 
Table 2 about here.  
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Table 2 illustrates the pattern of BMI and BMI change from pre-pregnancy to 1 year 
postpartum. BMI increased during pregnancy (3.2kg/m2 gained from pre-pregnancy to 1 
week postpartum). Women lost some of this weight across the postpartum year, with a mean 
BMI loss of 1.7kg/m2 from 1 week to 12 months. However, overall, women retained an 
average of 1.5kg/m2 at 12 months in comparison to their pre-pregnancy weight.  
 
Repeated Measures ANOVA demonstrated that BMI reduced significantly across the 
postnatal year (Pillai’s Trace F(4,45)=28.99, p<.0001, observed power =1). Posthoc pairwise 
comparisons showed significant postnatal reductions in BMI at all time points except 
between 6 and 12 months. All postnatal BMI measures were significantly higher than pre-
pregnancy BMI (p<.0001). Measures at one week were greater than BMI at any other time 
point (p<.0001). BMI at one month was greater than BMI at 6 and 12 months (p<.0001). BMI 
at 6 and 12 months were not significantly different (see Figure 1a).  
 
Maternal symptoms of postnatal depression across the postpartum year 
Repeated Measures ANOVA demonstrated that there was no significant change in postnatal 
depression symptoms across the postnatal year although there was a trend towards fewer 
symptoms with time (Pillai’s Trace F(2,47)=2.71, p<.077; observed power .51). Posthoc 
pairwise comparisons showed a significant decrease in postnatal depression symptoms 
between 1 month and 12 months only (p<.023) (see Figure 1b).  
 
Maternal glucocorticoid metabolism across the postpartum year 
Table 3 illustrates the pattern of cortisol metabolism from pre-pregnancy to 1 year 
postpartum. Steroid metabolite analysis from some of these individuals have been reported 
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elsewhere in the context of infant growth and development across the first year of life27. 
Presented in Table 3 are the urinary steroid metabolite ratios reflective of specific enzyme 
activities for mothers where detailed pre and post partum weight measurements are available. 
Repeated Measures ANOVAs demonstrated that there was no statistically significant change 
in 11ß-HSD-2 activity (F(4,22)=2, p=.13, observed power= .51) or Total F metabolites 
(F(4,22)= 1.6, p=.21, observed power =.41 ) across the year.  There was a significant increase 
in both 5α-reductase activity (F(4,22)= 44.5, p=.0001; observed power =1.0) and 11β-HSD-1 
activity (F(4,22)= 7.1, p=.001; observed power =.98). Post hoc pairwise comparisons showed 
a significant difference between 5α-reductase activity at 1 week and all other time points 
(p<.0001) and at 1 month and all other time points (p<.0001). Activity was higher at 3 
months than at 1 week and 1 month and lower than at 6 and 12 months (p<.05). There were 
no significant differences between 6 and 12-month 5α-reductase activity.  Differences in 11β-
HSD-1 were less profound but post hoc comparisons showed a significant difference in 11β-
HSD-1 activity between 1 week and 1 month, and between 1 week and 6 months (p<.05). 
11β-HSD-1 activity at 1 month was also lower than that at 3 and 6 months (p<.05). 11β-
HSD-1 at 3 months was lower than at 6 months (p<.05). Finally, 11β-HSD-1 activity at 6 
months was significantly higher than at 12 months (p<.05) (see Figure 1 c-f).  
Figure 1 about here  
 
To examine which variables were required as covariates in subsequent analyses, one tailed 
Pearson’s correlation coefficients between demographics, breastfeeding, symptoms of 
depression, postpartum ΔBMI and cortisol metabolism were calculated (Table 4). 
 
Table 4 about here 
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Table 4 demonstrates that postpartum ΔBMI showed no correlation with postnatal depression 
and few significant correlations with demographics. Women who smoked less during 
pregnancy had greater postpartum ΔBMI. Symptoms of postnatal depression were not 
correlated with demographics or breastfeeding duration. Postnatal depression symptoms at 12 
months were associated with greater total F metabolites at 12 months. Maternal age, income, 
education, smoking and alcohol consumption during pregnancy showed significant 
relationships with a number of indices of cortisol metabolism across the first year, and with 
5α-reductase activity in particular. Longer breastfeeding was associated with lower activity of 
11βHSD-2 and 5α-reductase at 1 month, and greater total F metabolites at 12 months. Before 
adjustment for covariates, women who showed greatest ΔBMI in the postpartum year had 
significantly lower 11β-HSD-1 activity at 12 months postpartum. Women with greater 11ß-
HSD-2 activity at 1 week showed more weight loss in the postpartum year.  Lower 5α-
reductase activity at all time points was associated with greater postpartum ΔBMI. Lower 
total F metabolites at 6 months were associated with greater weight loss. Post hoc power 
estimates for these correlation analyses suggest the sample was sufficient to detect 
meaningful relationships, i.e. where effect sizes were moderate (.3) to large (.5). At n=40, 
power to detect a correlation of .3 was .62; to detect a correlation of .5, power was .97. 
To examine the relationships between symptoms of postnatal depression with cortisol 
metabolism, and BMI change with cortisol metabolism, a series of partial correlations 
coefficients were calculated controlling for covariates (Table 5). Correlations between BMI 
change and cortisol metabolism were additionally adjusted for symptoms of depression at 12 
months.  
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Adjusted Relationships between symptoms of postnatal depression and maternal 
glucocorticoid metabolism across the postpartum year 
  
After adjusting for demographics and breastfeeding, the pattern of relationships between 
symptoms of postnatal depression and concurrent cortisol metabolism remained the same: 
women with poorer mental health at 12 months had greater concurrent total cortisol secretion 
rates. There were no other relationships between measures of depression and cortisol 
metabolism at any other time points.  
Adjusted Relationships between ΔBMI and maternal glucocorticoid metabolism across the 
postpartum year 
11ß-HSD activity  
After adjusting for covariates, greater ΔBMI was associated with significantly lower 11β-
HSD-1 activity at 1 week and 12 months postpartum. Women with greater 11ß-HSD-2 
activity at 1 week showed more weight loss in the postpartum year.  
5α-reductase activity  
Adjusting for covariates removed the significance of 5α-reductase activity at one week and 
one month, and reduced the relationship between 6-month 5α-reductase activity and ΔBMI to 
a trend. Lower 5α-reductase activity at 3 months and 1 year remained significantly associated 
with greater postpartum ΔBMI.  
Total F Metabolites 
After adjusting for covariates, there were no significant associations between total F 
metabolites and ΔBMI.  
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Discussion 
This study described maternal postpartum weight change, mental health and cortisol 
metabolism in a sample of healthy UK women across the postnatal year. Women experienced 
a mean BMI loss of 1.7kg/m2 from 1 week to 12 months postpartum and retained +1.5kg/m2 
at 12 months postpartum in comparison to their pre-pregnancy weight with notably large 
variability in postpartum weight change. Postnatal depression levels were as expected, 
showing slight decline across the year. Levels of 11ß-HSD-2 and Total F metabolites did not 
show significant change, but levels of 11ß-HSD-1 and 5α-reductase significantly increased 
between 1 week and 6 months postpartum, consistent with our previous analyses of a larger 
sample of this cohort24. However, there were few relationships between weight change and 
depression, demographics or breastfeeding duration. Indices of cortisol metabolism showed 
significant relationships with postnatal depression symptoms and postpartum weight change, 
underlining the importance of disturbances in the HPA axis for the prediction of postnatal 
weight change and mental health. However, the relationship between weight change and 
cortisol metabolism was independent of any relationship with depression.  
 
Over the post-partum year, we have identified changes in steroid hormone metabolism that 
are associated with maternal weight loss. Most notably, in line with our hypotheses, lower 
11β-HSD-1 and 5α-reductase activity was associated with enhanced weight loss when 
adjusted for covariates including depression. The role of steroid hormone metabolism in the 
regulation of weight has been extensively studied in the context of simple obesity and type 2 
diabetes31, but has not previously been examined in maternal post-partum weight.  
11β-HSD-1 generates active glucocorticoid, cortisol, in metabolic target tissues including 
adipose, liver and muscle32. Interestingly, all clinical studies that have used selective 11β-
HSD-1 inhibitors have demonstrated reproducible weight loss18,19,21 and in our cohort, lower 
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activity (at one week and 12 months) was associated with enhanced weight loss, which may 
reflect decreased adipocyte differentiation and lipid accumulation as a consequence of 
decreased tissue specific cortisol availability33. Although 11βHSD-2 is not thought to be 
expressed at significant levels in adipose tissue, the global increase in activity that we 
observed may also contribute to decreased tissue glucocorticoid availability. Only 11ßHSD-2 
activity at 1 week was associated with greater weight loss in the postnatal year, suggesting 
that urinary measures of this enzyme are not key determinants of postnatal weight loss nor 
key correlates of postnatal depression in healthy participants. 
Lower 5α-reductase activity at 3 and 12 months postpartum was associated with increased 
weight loss. There are 2 isoforms of 5α-reductase (type 1 and type 2) that have differential 
tissue specific expression profiles and both contribute to steroid hormone metabolism.34 
Cross-sectional studies have demonstrated the association between increased 5α-reductase 
activity and adverse metabolic phenotype16,17,35. This extends to simple obesity, non-alcoholic 
fatty liver disease and the adverse metabolic phenotype associated with polycystic ovary 
syndrome. Weight loss is associated with a reduction of 5α-reductase activity22. 5α-reductase 
clears glucocorticoids to their inactive dihydro-metabolites (subsequently converted to 
tetrahydro-metabolites by the action of 3α-hydroxysteroid dehydrogenase) and therefore 
limiting glucocorticoid availability to bind and activate the glucocorticoid receptor. In 
addition, they have a role in activating androgens, converting testosterone to the more potent 
androgen dihydrotestosterone. Lowering activity has the potential to decrease androgen 
availability whilst simultaneously reducing glucocorticoid clearance, and both androgens and 
glucocorticoids regulate fat mass. What remains unclear is whether changes in 5α-reductase 
reflect cause or consequence of changes in postpartum BMI; the associations that we have 
described cannot infer causality. Rodent models with genetic deletion of 5α-reductase type 1 
have an adverse metabolic phenotype, largely confined to the liver without alteration in fat 
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mass36. Clinical studies in patients have shown that non-selective 5α-reductase inhibition 
(type 1 and 2), but not exclusive type 2 inhibition, is associated with systemic and hepatic 
insulin resistance and with hepatic lipid accumulation37. Taken together, it seems likely that 
the changes that we have observed in 5α-reductase activity reflect a compensatory response 
such that with weight gain, glucocorticoid availability to bind and activate its receptor is 
limited. This may occur in response to the increased adrenal glucocorticoid output that is seen 
with increased weight 38. As weight falls, adrenal glucocorticoid output falls and as a result 
there is no longer the need to repress local glucocorticoid availability and in parallel 
therefore, 5α-reductase activity decreases. Therefore, patients with the largest weight loss 
display greatest reduction in 5α-reductase activity. 
Total glucocorticoid production was significantly correlated with depression symptoms at 12 
months, but there were no relationships between postnatal depression at any other time point 
or any other measures of cortisol metabolism. However, 6% of the women in the sample had 
EPDS scores indicating probable major depression at 12 months and mean EPDS score was 
5, comparable to other relatively mentally healthy UK postnatal samples39. Despite this, 
women with more depression symptoms at 12 months had greater total cortisol metabolite 
production, previously associated with greater BMI and abnormal glucose tolerance17. The 
causal nature and long term implications of this relationship is impossible to determine from 
our data, but are consistent with the suggestion that women with greater, and/or more 
persistent, symptoms of postnatal depression may be at greater risk for the development of 
metabolic disorders. 
The clinical implications of these findings are limited at this stage given the healthy nature of 
our sample. However, for women with a problematic postnatal weight loss trajectory, 
selective 11β-HSD-1 inhibitors could be investigated as an adjunct to diet and lifestyle 
intervention to aid weight loss. Furthermore, examination of total glucocorticoid production 
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using spot urine samples has the potential to offer a more personalised approach to the 
evaluation of future metabolic and mental health risk.   
In general, our findings regarding links between maternal postnatal mental health, weight 
retention and cortisol metabolism in this healthy sample show similarities to the patterns 
found in severely obese women, when serum cortisol levels were measured13; mental health 
was related to cortisol level, cortisol level was related to postnatal weight retention but 
cortisol level did not mediate the relationship between weight and mental health. Together, 
these studies provide evidence to support that weight and mental health are both associated 
with dysregulation of glucocorticoid secretion and metabolism, but that there may be 
different pathways to depression and obesity. There are other important contributors 
to/moderators of the development of each phenotype that were not examined in this study, 
such as early biological programming, gene expression or experience of stress. Further work 
is required to better understand these pathways and their contributors to both physical and 
psychological postpartum morbidity. 
There are a number of limitations of this study. This was a relatively healthy weight sample 
with low levels of depression and our conclusions cannot be extrapolated to obese or 
depressed populations. The absence of expected relationships, such as that between weight 
change and depression, may be a result of this limitation. Furthermore, the sample was 
predominantly White, well educated, affluent, with high levels of breastfeeding. There are 
likely to be important demographic patterns in the relationships between weight retention, 
depression and cortisol metabolism that this study could not capture. In addition, we did not 
collect data on stressors such as sleep deprivation, which may have an impact on both mental 
health and cortisol metabolism40. Finally, we did not correct for multiple testing to reduce the 
risk of a type II error in this small exploratory study, which naturally increases risk of a type I 
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error. Therefore these findings, whilst important for future hypothesis generation, require 
replication.  
In summary, this study significantly expands our understanding of the relationships between 
cortisol metabolism, mental health and weight change postpartum.  Lower activity of 11β-
HSD-1 and 5α-reductase was associated with greater postpartum weight loss in healthy 
women, independent of demographics and depression. More depressed women also 
demonstrated higher cortisol secretion rates, independent of demographics and breastfeeding, 
but depression was unrelated to BMI change. In healthy samples, cortisol metabolism is 
related to both BMI and symptoms of depression, but weight and depressed mood have 
independent pathways that link them to HPA activity.  
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Figure Legend: 
Figure 1: Patterns of 1a: postnatal depression (EPDS score), 1b: BMI (kg/m2) 1c) 5α-
reductase activity, 1d) 11β-HSD-1 activity, 1e) 11β-HSD-2 activity and 1f) Total F 
metabolites across the postpartum year. Means with different letters are significantly different 
to each other at p<.05. 
 
Table 1: Demographics (%), concurrent BMI measures and symptoms of depression (Mean, 
SD) at each time point for the whole sample (N=49; column 2) and for all mothers providing 
urine samples at each time point (columns 3-7).  
 Whole sample  
(n=49) 
1 week 
(n=40) 
1 month 
(n=46) 
3 
months 
(n=42) 
6 
months 
(n=45) 
12 
months 
(n=39) 
Maternal age 
(years)  
Mean (SD) 
30.8 (5.5) 31.4 
(5.0) 
30.9 
(5.6) 
30.9 
(5.4) 
31.0 
(5.3) 
30.9 
(5.6) 
Maternal 
concurrent BMI 
(kg/m2)  
Mean (SD) 
27.0 (3.7) @1 wk 
26.5 (3.6) @1 mo 
25.7 (3.8) @6 mo 
25.3 (3.7) @12 mo 
26.7 
(3.7) 
26.2 
(3.6) 
 
- 25.6 
(3.9) 
 
25.3 
(3.9) 
 
EPDS score 
Mean (SD) 
6.3 (4.6) @1 mo 
5.7 (4.5) @6 mo 
4.9 (4.4) @12 mo 
- 6.1 (4.6) - 5.4 (4.4) 4.9 (4.7) 
Percent (n) 
depressed 
(EPDS ≥13) 
8% (4) @1 mo 
4% (2) @6 mo 
6% (3) @12 mo 
- 8.7% (4) - 4.4% (2) 7.7% (3)
Percent  (n) 
some 
breastfeeding  
82% (40) @1 wk 
71% (35) @1 mo 
63% (31) @3 mo 
59% (29) @6 mo 
33% (16) @12 mo 
85% 
(34) 
70% 
(32) 
69% 
(29) 
62% 
(28) 
33% 
(13) 
Percent  (n) 
Infant gender 
55% (27) male 65% 
(26) 
male 
58.7%  
(27) 
male 
54.8% 
(23) 
male 
57.8% 
(26) 
male 
56.4% 
(22) 
male 
Percent  (n) 
Degree 
educated  
41% (20)  45% 
(18) 
43.5% 
(20) 
45% 
(19) 
42.2% 
(19) 
41% 
(16) 
Percent  (n) In 
highest income 
65% (32) 77.5% 
(31) 
67.4% 
(31) 
69% 
(29) 
68.9% 
(31) 
66.7% 
(26) 
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bracket 
Percent  (n) 
Smoked in 
pregnancy 
10% (5) 7.5% (3) 6.5% (3) 9.5% (4) 8.9% (4) 10% (4) 
Percent  (n) 
Consumed 
alcohol in 
pregnancy 
43% (21) 50% 
(20) 
43.5% 
(20) 
45.2% 
(19) 
44.4% 
(20) 
43.6% 
(17) 
Percent  (n) 
Primary ethnic 
groups 
57% (28) White 
British 
12% (6) White 
Other 
12% (6) Asian 
Pakistani 
57.5% 
(23) 
White 
British 
12.5% 
(5) 
White 
Other 
10% (4) 
Asian 
Pakistan
i 
58.7% 
(27) 
White 
British 
13% (6) 
White 
Other 
10.9% 
(5) 
Asian 
Pakistan
i 
54.8% 
(23) 
White 
British 
14.3% 
(6) 
White 
Other 
9.5% (4) 
Asian 
Pakistan
i 
57.8% 
(26) 
White 
British 
13.3% 
(6) 
White 
Other 
8.9% (4) 
Asian 
Pakistan
i 
61.5% 
(24) 
White 
British 
15.4% 
(6) 
White 
Other 
7.7% 
Asian 
Pakistan
i (3) 
7.7% (3) 
Black 
Caribbe
an 
N sizes for each time point vary because some mothers did not produce urine samples for all 
visits.  Percentages in columns 3-7 are expressed as a function of the number of women 
providing urine samples at each time point. 
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Table 2: BMI and ΔBMI from pre-pregnancy to 1 year postpartum (N=49). BMI expressed 
as (kg/m2)  
 Minimum Maximum Mean Std. 
Deviation 
Pre-pregnancy BMI 18.8 31.9 23.8 3.1 
1-week maternal BMI 19.2 35.7 27.0 3.7 
1 month maternal BMI 18.8 35.9 26.5 3.6 
6 month maternal BMI 19.5 35.2 25.7 3.8 
12 month maternal BMI 18.9 36.4 25.3 3.8 
ΔBMI pre-pregnancy to 1 week 
postpartum 
-8.1 .7 -3.2 2.3 
ΔBMI 1 week postpartum to 1 
month postpartum 
-.4 3.3 .5 .7 
ΔBMI 1 month postpartum to 6 
months postpartum 
-2.5 4.7 .8 1.6 
ΔBMI 6 months postpartum to 
12 months postpartum  
-5.4 3.1 .4 1.5 
ΔBMI pre-pregnancy to 12 
months postpartum 
-7.6 3.0 -1.5 2.4 
ΔBMI 1 week postpartum to 12 
months postpartum 
-4.6 7.8 1.7 2.3 
ΔBMI = change in BMI (kg/m2). Positive ΔBMI is indicative of weight loss. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3: Urinary steroid metabolite ratios as measured by gas chromatography / mass 
spectrometry across the first post-partum year. 
THF =tetrahydrocortisol, THE =tetrahydrocortisone, E=cortisone, F=cortisol 
  
Steroid ratio Time point N Min. Max. Mean SD 
THF+5αTHF/ THE 
 
(11β-HSD-1 activity;  
conversion of cortisone to 
cortisol) 
1-week 40 0.45 1.31 0.86 0.2
1 month 46 0.48 1.21 0.83 0.18
3 months 42 0.51 1.55 0.89 0.24
6 months 45 0.56 1.47 0.99 0.21
12 months 39 0.5 1.3 0.84 0.20
F/E 
 
(11-βHSD-2 activity;  
conversion of cortisol to 
cortisone) 
1-week 40 0.39 1.69 0.8 0.26
1 month 46 0.33 2.19 0.67 0.29
3 months 42 0.36 1.39 0.65 0.23
6 months 45 0.36 1.93 0.65 0.25
12 months 39 0.29 1.33 0.63 0.24
5αTHF/THF 
 
(5α-reductase activity ;  
clearance of cortisol to 
tetrahydrometabolites) 
1-week 40 0.08 0.46 0.2 0.09
1 month 46 0.11 1.32 0.47 0.29
3 months 42 0.24 2.32 0.85 0.43
6 months 45 0.18 3.17 1.00 0.59
12 months 39 0.35 2.5 0.99 0.43
Total F Metabolites 
  
(μg/g urinary creatinine;  
total cortisol metabolite 
production) 
1-week 40 1123.0 17489.0 6346.6 4277.7
1 month 46 728.0 19811.0 7784.9 5091.3
3 months 42 1515.0 31204.0 7472.8 6496.3
6 months 45 1023.0 27826.0 9849.1 8278.4
12 months 39 1374.0 28322.0 8990.8 6942.1
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Table 4. Unadjusted one tailed Pearson’s correlation coefficients between demographics, pregnancy 
smoking, pregnancy alcohol consumption, breastfeeding duration, with ∆BMI and cortisol metabolism.  
 Ti
m
e
 ∆B
M
I 
 Co
nc
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rr
e
n
t  
EP
D
S 
 
M
at
er
n
a
l a
ge
 
In
co
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e
 
Ed
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a
tio
n
 
Sm
ok
in
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Al
co
ho
l  
To
ta
l B
re
a
st
 -
fe
ed
in
g 
D
ur
a
tio
n
  
∆BMI 
 
1 week-  
12 months 
- - .17 .18 -.01 -.32* .10 .03 
Depression 
(EPDS)  
 
1month -.13 - -.01 .05 -.05 .15 .01 .11 
6 months -.02 - .05 .08 -.01 .04 .07 .11 
12 months  -.05 - -.03 .10 -.07 .06 .13 .02 
11β-HSD-1 
 
THF+5aTHF/
THE 
 
1 week -.23t - .04 .17 .25 -.24 .13 -.11 
1 month -.16 -.15 .22 -.25* .16 -.22 -.01 .15 
3 months -.21t - .09 -.03 .06 .29* -.14 -.02 
6 months .06 .02 -.03 .02 .06 -.03 .02 -.18 
12 months -.32* -.16 -.01 -.10 -.10 .18 -.24 -.06 
11β-HSD-2† 
 
F/E 
 
1 week -.35* - -.24 -.22 -.38** .10 -.12 -.08 
1 month .04 -.02 .19 .09 .02 -.03 .30* .28* 
3 months -.06 - .04 .02 -.13 .27* -.22 .25 
6 months .03 .01 -.20 -.03 .07 .05 .17 -.04 
12 months .09 .09 -.20 -.11 -.30* .18 .01 -.04 
5α-reductase 
 
5aTHF/THF 
 
1 week -.29* - -.28* -.41** -.18 .58*** -.23 -.06 
1 month -.31* .12 -.28* -.45** -.29* .27* -.18 -.28* 
3 months -
.45** 
- -.38** -.29* -.24 .50*** -.21 -.22 
6 months -
.40** 
.08 -.29* -.20 -.17 .54*** -.29* -.14 
12 months -
.39** 
.00 -.19 -.28* -.29* .28* -.26 .13 
Total F 
Metabolites 
1 week -.03 - .02 -.05 -.19 .25 -.23 .12 
1 month -.14 -.13 -.06 -.02 .03 .17 .01 -.19 
3 months -.07 - -.20 -.24 -.06 -.12 -.08 -.04 
6 months -.26* -.01 -.26* -.23 -.13 .45** -.25* .09 
12 months .03 .43** -.06 -.18 -.19 .33* -.12 .43** 
*p<.05, **p<.01, ***p<.001 † greater F/E ratios indicate lower 11βHSD-2 activity.   
THF =tetrahydrocortisol, THE =tetrahydrocortisone, E=cortisone, F=cortisol 
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Table 5: 1 Tailed partial correlation coefficients between cortisol metabolism and maternal 
symptoms of depression at 1, 6 and 12 months and ΔBMI. 
t=trend: p<.1; *p<.05; **p<.01 † greater F/E ratios indicate lower 11βHSD-2 activity. 
THF =tetrahydrocortisol, THE =tetrahydrocortisone, E=cortisone, F=cortisol.  
§ Analyses adjusted for demographics and breastfeeding duration. ΔBMI and cortisol 
metabolism analyses adjusted for demographics, breastfeeding duration and symptoms of 
postnatal depression at 12 months. 
 
  
 Time EPDS§ ΔBMI  
1 week to 12 
months§ 
11β-HSD-1 
 
conversion of cortisone 
to cortisol; 
THF+5aTHF/THE 
1 week - -.39* 
1 month -.10 -.20 
3 months - -.17 
6 months .05 .05 
12 months -.14 -.30* 
11β-HSD-2† 
 
conversion of cortisol to 
cortisone; F/E 
1 week - -.36* 
1 month -.09 .01 
3 months - -.05 
6 months .01 .07 
12 months .03 .15 
5α-reductase 
 
clearance of cortisol to 
tetrahydrometabolites; 
5aTHF/THF 
1 week - -.01 
1 month .17 -.18 
3 months - -.33* 
6 months .13 -.25t 
12 months -.01 -.33* 
Total F Metabolites 
 
Total cortisol secretion 
rate;  μg/g urinary 
creatinine 
1 week - .07 
1 month -.16 -.08 
3 months - .10 
6 months -.01 -.01 
12 months .50** .28t 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
